IN189722B - - Google Patents

Info

Publication number
IN189722B
IN189722B IN1694DE1998A IN189722B IN 189722 B IN189722 B IN 189722B IN 1694DE1998 A IN1694DE1998 A IN 1694DE1998A IN 189722 B IN189722 B IN 189722B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN189722(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IN189722B publication Critical patent/IN189722B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1694DE1998 1997-06-18 1998-06-18 IN189722B (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
IN189722B true IN189722B (cg-RX-API-DMAC10.html) 2003-04-19

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1694DE1998 IN189722B (cg-RX-API-DMAC10.html) 1997-06-18 1998-06-18

Country Status (38)

Country Link
US (3) US20060100247A1 (cg-RX-API-DMAC10.html)
EP (2) EP1787646A3 (cg-RX-API-DMAC10.html)
JP (1) JP2002504137A (cg-RX-API-DMAC10.html)
KR (2) KR20060105005A (cg-RX-API-DMAC10.html)
CN (2) CN1230171C (cg-RX-API-DMAC10.html)
AP (1) AP1279A (cg-RX-API-DMAC10.html)
AR (2) AR012998A1 (cg-RX-API-DMAC10.html)
AT (1) ATE355840T1 (cg-RX-API-DMAC10.html)
AU (1) AU8539398A (cg-RX-API-DMAC10.html)
BG (2) BG64818B1 (cg-RX-API-DMAC10.html)
BR (1) BR9810172A (cg-RX-API-DMAC10.html)
CA (1) CA2294582C (cg-RX-API-DMAC10.html)
CY (2) CY1107643T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ298469B6 (cg-RX-API-DMAC10.html)
DE (2) DE122007000054I1 (cg-RX-API-DMAC10.html)
DK (1) DK0996444T3 (cg-RX-API-DMAC10.html)
DZ (1) DZ2520A1 (cg-RX-API-DMAC10.html)
EA (1) EA003144B1 (cg-RX-API-DMAC10.html)
ES (1) ES2284212T3 (cg-RX-API-DMAC10.html)
ID (1) ID23372A (cg-RX-API-DMAC10.html)
IL (3) IL133142A0 (cg-RX-API-DMAC10.html)
IN (1) IN189722B (cg-RX-API-DMAC10.html)
LU (1) LU91356I2 (cg-RX-API-DMAC10.html)
MA (1) MA26512A1 (cg-RX-API-DMAC10.html)
MY (1) MY129897A (cg-RX-API-DMAC10.html)
NL (1) NL300288I2 (cg-RX-API-DMAC10.html)
NO (4) NO324993B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ501260A (cg-RX-API-DMAC10.html)
OA (1) OA11516A (cg-RX-API-DMAC10.html)
PE (1) PE83199A1 (cg-RX-API-DMAC10.html)
PL (2) PL195140B1 (cg-RX-API-DMAC10.html)
PT (1) PT996444E (cg-RX-API-DMAC10.html)
SI (1) SI0996444T1 (cg-RX-API-DMAC10.html)
SK (1) SK286029B6 (cg-RX-API-DMAC10.html)
TR (1) TR199903057T2 (cg-RX-API-DMAC10.html)
TW (1) TW565449B (cg-RX-API-DMAC10.html)
UY (1) UY25049A1 (cg-RX-API-DMAC10.html)
WO (1) WO1998057634A1 (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE69818444T2 (de) * 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
BR0015294A (pt) 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
AU5745601A (en) * 2000-05-01 2001-11-12 Aeropharm Technology Inc A core formulation
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
ES2529180T3 (es) * 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
WO2004067001A1 (ja) 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
EP1772149A1 (en) * 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US20090137626A1 (en) * 2005-07-12 2009-05-28 Akira Okuno Pharmaceutical Composition Containing PPARgamma Agonist
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
ES2294980T1 (es) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
JP2012503595A (ja) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CN104349773A (zh) 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
MY129897A (en) 2007-05-31
CA2294582A1 (en) 1998-12-23
PT996444E (pt) 2007-06-08
US20060100247A1 (en) 2006-05-11
BG104060A (en) 2000-10-31
LU91356I2 (fr) 2008-01-29
DE69837261D1 (de) 2007-04-19
NZ501260A (en) 2002-09-27
KR20010013844A (ko) 2001-02-26
NL300288I2 (nl) 2009-06-02
DZ2520A1 (fr) 2003-02-01
CN1429551A (zh) 2003-07-16
EA003144B1 (ru) 2003-02-27
EP0996444B1 (en) 2007-03-07
SK179299A3 (en) 2000-11-07
PE83199A1 (es) 1999-10-22
UY25049A1 (es) 2000-09-29
SI0996444T1 (sl) 2007-08-31
PL337362A1 (en) 2000-08-14
AP1279A (en) 2004-05-20
OA11516A (en) 2004-02-04
CZ298469B6 (cs) 2007-10-10
NO326958B1 (no) 2009-03-23
NO2008003I2 (no) 2010-06-28
CN1260716A (zh) 2000-07-19
BG109398A (bg) 2006-05-31
BG64818B1 (bg) 2006-05-31
AR012998A1 (es) 2000-11-22
KR20060105005A (ko) 2006-10-09
NL300288I1 (nl) 2007-11-01
AU8539398A (en) 1999-01-04
AR012995A1 (es) 2000-11-22
PL195140B1 (pl) 2007-08-31
US20070004780A1 (en) 2007-01-04
EP1787646A2 (en) 2007-05-23
IL173650A0 (en) 2006-07-05
CY1107643T1 (el) 2012-01-25
NO2008003I1 (no) 2008-04-21
EP0996444A1 (en) 2000-05-03
SK286029B6 (sk) 2008-01-07
DE122007000054I1 (de) 2007-12-13
CY2007018I1 (el) 2012-01-25
IL133142A (en) 2006-06-11
MA26512A1 (fr) 2004-12-20
HK1028193A1 (en) 2001-02-09
BR9810172A (pt) 2000-08-08
DE69837261T2 (de) 2007-11-08
NO996266D0 (no) 1999-12-17
NO20090846L (no) 1999-12-17
CZ9904578A3 (en) 2001-06-13
JP2002504137A (ja) 2002-02-05
CA2294582C (en) 2008-02-12
DK0996444T3 (da) 2007-07-02
NO324993B1 (no) 2008-01-14
ATE355840T1 (de) 2007-03-15
PL195136B1 (pl) 2007-08-31
WO1998057634A1 (en) 1998-12-23
EA200000041A1 (ru) 2000-08-28
AP9901719A0 (en) 1999-12-31
EP1787646A3 (en) 2007-10-03
CN1114404C (zh) 2003-07-16
US20080090881A1 (en) 2008-04-17
TR199903057T2 (xx) 2000-04-21
ID23372A (id) 2000-04-20
KR100666591B1 (ko) 2007-01-11
NO20063000L (no) 1999-12-17
TW565449B (en) 2003-12-11
CN1230171C (zh) 2005-12-07
ES2284212T3 (es) 2007-11-01
NO996266L (no) 1999-12-17
IL133142A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
BE2018C032I2 (cg-RX-API-DMAC10.html)
ITMI971273A0 (cg-RX-API-DMAC10.html)
GB9711447D0 (cg-RX-API-DMAC10.html)
IN189879B (cg-RX-API-DMAC10.html)
BE2013C047I2 (cg-RX-API-DMAC10.html)
ITMI971551A0 (cg-RX-API-DMAC10.html)
ITMI970993A0 (cg-RX-API-DMAC10.html)
ITMI971553A0 (cg-RX-API-DMAC10.html)
IN183682B (cg-RX-API-DMAC10.html)
IN186198B (cg-RX-API-DMAC10.html)
IN186499B (cg-RX-API-DMAC10.html)
ITAR970020A0 (cg-RX-API-DMAC10.html)
ITVE970022V0 (cg-RX-API-DMAC10.html)
ITMI971366A0 (cg-RX-API-DMAC10.html)
ITCA970017A0 (cg-RX-API-DMAC10.html)
IN185743B (cg-RX-API-DMAC10.html)
CN3056367S (cg-RX-API-DMAC10.html)
CN3053170S (cg-RX-API-DMAC10.html)
CN3053248S (cg-RX-API-DMAC10.html)
CN3056358S (cg-RX-API-DMAC10.html)
CN3053002S (cg-RX-API-DMAC10.html)
CN3056419S (cg-RX-API-DMAC10.html)
CN3053524S (cg-RX-API-DMAC10.html)
CN3055551S (cg-RX-API-DMAC10.html)
CN3054902S (cg-RX-API-DMAC10.html)